NCT02210949

Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery

Pre-operative Treatment With Erythropoietin and Iron Supplement for Prevention of Perioperative Blood Transfusion in Cardiac Surgery

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Catharina Ziekenhuis Eindhoven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pre-treatment of patients with erythropoietin subcutaneously and iron supplement intravenously, in order to create a clinical pathway to minimize transfusion of red blood cells in a selected group of cardiac patients with an increased risk for blood transfusions in our cardiac surgery program.

Detailed description

Blood transfusion is identified as an independent predictor of early mortality after Coronary artery bypass grafting operations In addition, female gender, lower body surface area (BSA), low preoperative Hemoglobin (Hb), previous cardiac surgery, emergency operation and low preoperative creatinin clearance were found to be independent risk factors for receiving Red Blood Cells (RBC) units. We create a clinical pathway to reduce transfusion of red blood cells by pretreating patients with erythropoietin and iron to determine the reduction of number of patients who receive blood transfusion perioperatively. Also we want to investigate the decrease in the mean number of RBC units received per patient in the perioperative period.

Conditions

• Heart; Dysfunction Postoperative, Cardiac Surgery
• Anemia, Iron-Deficiency

Interventions

Type	Name	Description
DRUG	Erythropoietin subcutaneously and Iron intravenously	Administration of Erythropoietin subcutaneously and administration of iron intravenously

Timeline

• Start date: 2014-08-01
• Primary completion: 2017-04-01
• Completion: 2017-04-01
• First posted: 2014-08-07
• Last updated: 2017-04-05

Locations

1 site across 1 country: Netherlands